ELSEVIER

Diabetes Research and Clinical Practice 59 (2003) 235–237

DIABETES RESEARCH AND CLINICAL PRACTICE

www.elsevier.com/locate/diabres

# Author index of volume 59

Adachi, T., see Yasuda, K. **59**, 113
Aguilar, M., see Carral, F. **59**, 145
Ajayi, A.A., H. Hercule, J. Cory, B.E. Hayes, A.O. Oyekan, Gender difference in vascular and platelet reactivity to thromboxane $A_2$-mimetic U46619 and to endothelial dependent vasodilation in Zucker fatty (hypertensive, hyperinsulinemic) diabetic rats **59**, 11
Allen, T.J., see Little, P.J. **59**, 93
Armstrong, D.G., see Vazquez, J.R. **59**, 123
Atsumi, Y., see Suzuki, Y. **59**, 233
Azuma, J., see Yamamoto, I. **59**, 219

Bajotto, G., see Hu, X. **59**, 103
Boulton, A.J.M., see Vazquez, J.R. **59**, 123
Buyukbese, M.A., see Ozdemir, M. **59**, 195

Carral, F., G. Olveira, M. Aguilar, J. Ortego, I. Gavilán, I. Doménech, L. Escobar, Hospital discharge records underreport the prevalence of diabetes in inpatients **59**, 145
Cetinkaya, A., see Ozdemir, M. **59**, 195
Chiang, C.-C., see Wei, J.-N. **59**, 201
Chiasson, J.-L., see Josse, R.G. **59**, 37
Chou, P., see Li, C.-L. **59**, 225
Chuang, L.-M., see Wei, J.-N. **59**, 201
Cory, J., see Ajayi, A.A. **59**, 11

Dakovska, L., see Tankova, T. **59**, 43
Dilley, R.J., see Little, P.J. **59**, 93
Doménech, I., see Carral, F. **59**, 145
Dornan, J.M., see Josse, R.G. **59**, 37

Eisenbarth, G.S., see Graves, P.M. **59**, 51
Ekangaki, A., see Mattoo, V. **59**, 137
Erlich, H.A., see Graves, P.M. **59**, 51
Escobar, L., see Carral, F. **59**, 145

Farrelly, C.A., see Little, P.J. **59**, 93
Findlow, A.H., see Vazquez, J.R. **59**, 123
Fujita, T., see Onozato, M.L. **59**, 83
Fujitsu, J., see Yamamoto, I. **59**, 219
Fukui, M., Y. Kitagawa, N. Nakamura, S. Mogami, M. Ohnishi, C. Hirata, N. Ichio, K. Wada, K. Kamiuchi, M. Shigeta, M. Sawada, G. Hasegawa, T. Yoshikawa, Augmentation of central arterial pressure as a marker of atherosclerosis in patients with type 2 diabetes **59**, 153
Fukushima, M., see Kuroe, A. **59**, 71

Gavilán, I., see Carral, F. **59**, 145
Gerstein, H., see Josse, R.G. **59**, 37
Goto, A., see Onozato, M.L. **59**, 83
Graves, P.M., H.A. Rotbart, W.A. Nix, M.A. Pallansch, H.A. Erlich, J.M. Norris, M. Hoffman, G.S. Eisenbarth, M. Rewers, Prospective study of enteroviral infections and development of beta-cell autoimmunity: Diabetes autoimmunity study in the young (DAISY) **59**, 51
Guhl, D.J., see Martinez, D.A. **59**, 1

Han, L., see Tian, H. **59**, 63
Hasegawa, G., see Fukui, M. **59**, 153
Hashimura, K., see Little, P.J. **59**, 93
Hayes, B.E., see Ajayi, A.A. **59**, 11
Hercule, H., see Ajayi, A.A. **59**, 11
Hirata, C., see Fukui, M. **59**, 153
Hoffman, M., see Graves, P.M. **59**, 51
Hosoi, T., see Kazama, H. **59**, 181
Hosokawa, M., see Yasuda, K. **59**, 113
Hu, X., J. Sato, Y. Oshida, M. Xu, G. Bajotto, Y. Sato, Effect of Gosha-jinki-gan (Chinese herbal medicine: Niu-Che-Sen-Qi-Wan) on insulin resistance in streptozotocin-induced diabetic rats **59**, 103

Ichio, N., see Fukui, M. **59**, 153
Igarashi, T., see Yamamoto, I. **59**, 219
Iizuka, K., see Nagai, T. **59**, 191
Ikeda, M., see Kuroe, A. **59**, 71
Ikehara, K., H. Tada, K. Kuboki, T. Inokuchi, Role of protein kinase C-angiotensin II pathway for extracellular matrix production in cultured human mesangial cells exposed to high glucose levels **59**, 25

PII: S0168-8227(03)00024-X

Imamura, M., see Nagai, T. **59**, 191
Inaba, M., see Yamamoto, I. **59**, 219
Inokuchi, T., see Ikehara, K. **59**, 25
Ito, H., see Kazama, H. **59**, 181

Josse, R.G., J.-L. Chiasson, E.A. Ryan, D.C.W. Lau, S.A. Ross, J.-F. Yale, L.A. Leiter, P. Maheux, D. Tessier, T.M.S. Wolever, H. Gerstein, N.W. Rodger, J.M. Dornan, L.J. Murphy, R. Rabasa-Lhoret, G.S. Meneilly, Acarbose in the treatment of elderly patients with type 2 diabetes **59**, 37

Kadowaki, T., see Suzuki, S. **59**, 207
Kamiuchi, K., see Fukui, M. **59**, 153
Kanatsuka, A., see Suzuki, S. **59**, 207
Kang, M.-H., see Kim, H.-K. **59**, 129
Kazama, H., S. Usui, M. Okazaki, T. Hosoi, H. Ito, H. Orimo, Effects of bezafibrate and pravastatin on remnant-like lipoprotein particles and lipoprotein subclasses in type 2 diabetes **59**, 181
Kim, H.-K., S.-K. Lee, C.-J. Suh, H.-J. Yoon, K.-Y. Lee, H.-Y. Park, M.-H. Kang, Postchallenge hyperglycemia but not hyperinsulinemia is associated with angiographically documented coronary atherosclerosis in Korean subjects **59**, 129
Kirilov, G., see Tankova, T. **59**, 43
Kitagawa, Y., see Fukui, M. **59**, 153
Kobayashi, M., see Suzuki, S. **59**, 207
Koev, D., see Tankova, T. **59**, 43
Kuboki, K., see Ikehara, K. **59**, 25
Kuroe, A., M. Fukushima, M. Usami, M. Ikeda, Y. Nakai, A. Taniguchi, T. Matsuura, H. Suzuki, T. Kurose, K. Yasuda, Y. Yamada, Y. Seino, Impaired β-cell function and insulin sensitivity in Japanese subjects with normal glucose tolerance **59**, 71
Kurose, T., see Kuroe, A. **59**, 71
Kuzuya, T., see Suzuki, S. **59**, 207

Lau, D.C.W., see Josse, R.G. **59**, 37
Lee, K.-Y., see Kim, H.-K. **59**, 129
Lee, S.-K., see Kim, H.-K. **59**, 129
Leiter, L.A., see Josse, R.G. **59**, 37
Levitt, L.K., see Mattoo, V. **59**, 137
Liang, J., see Tian, H. **59**, 63
Li, C.-L., S.-T. Tsai, P. Chou, Relative role of insulin resistance and β-cell dysfunction in the progression to type 2 diabetes—The Kinmen Study **59**, 225
Lin, C.-C., see Wei, J.-N. **59**, 201
Lin, R.-S., see Wei, J.-N. **59**, 201
Liong, L.H.C., see Mattoo, V. **59**, 137
Little, P.J., T.J. Allen, K. Hashimura, J. Nigro, C.A. Farrelly, R.J. Dilley, High glucose potentiates mitogenic responses of cultured ovine coronary smooth muscle cells to platelet derived growth factor and transforming growth factor-β1 **59**, 93
Li, X., see Tian, H. **59**, 63

Maheux, P., see Josse, R.G. **59**, 37
Malone, J.K., see Mattoo, V. **59**, 137
Martinez, D.A., D.J. Guhl, W.C. Stanley, A.C. Vailas, Extracellular matrix maturation in the left ventricle of normal and diabetic swine **59**, 1
Matsuura, T., see Kuroe, A. **59**, 71
Mattoo, V., Z. Milicevic, J.K. Malone, M. Schwarzenhofer, A. Ekangaki, L.K. Levitt, L.H.C. Liong, N. Rais, H. Tounsi, A comparison of insulin lispro Mix25™ and human insulin 30/70 in the treatment of type 2 diabetes during Ramadan **59**, 137
Matusoka, K., see Suzuki, Y. **59**, 233
Meneilly, G.S., see Josse, R.G. **59**, 37
Milicevic, Z., see Mattoo, V. **59**, 137
Mogami, S., see Fukui, M. **59**, 153
Mori, M., see Nagai, T. **59**, 191
Motomura, T., see Yamamoto, I. **59**, 219
Murphy, L.J., see Josse, R.G. **59**, 37

Nagai, T., M. Imamura, K. Iizuka, M. Mori, Hypoglycemia due to nateglinide administration in diabetic patient with chronic renal failure **59**, 191
Nagashima, K., see Yasuda, K. **59**, 113
Nakai, Y., see Kuroe, A. **59**, 71
Nakamura, N., see Fukui, M. **59**, 153
Nanjo, K., see Suzuki, S. **59**, 207
Nigro, J., see Little, P.J. **59**, 93
Nixon, B.P., see Vazquez, J.R. **59**, 123
Nix, W.A., see Graves, P.M. **59**, 51
Nohnen, S., see Yamamoto, I. **59**, 219
Norris, J.M., see Graves, P.M. **59**, 51

Odaka, H., see Yasuda, K. **59**, 113
Ohnishi, M., see Fukui, M. **59**, 153
Oka, Y., see Suzuki, S. **59**, 207
Okazaki, M., see Kazama, H. **59**, 181
Olveira, G., see Carral, F. **59**, 145
Onozato, M.L., A. Tojo, A. Goto, T. Fujita, Effect of combination therapy with dipyridamole and quinapril in diabetic nephropathy **59**, 83
Orimo, H., see Kazama, H. **59**, 181
Ortego, J., see Carral, F. **59**, 145
Oshida, Y., see Hu, X. **59**, 103
Oyekan, A.O., see Ajayi, A.A. **59**, 11
Ozdemir, G., see Ozdemir, M. **59**, 195
Ozdemir, M., M.A. Buyukbese, A. Cetinkaya, G. Ozdemir, Risk factors for ocular surface disorders in patients with diabetes mellitus **59**, 195

Pallansch, M.A., see Graves, P.M. **59**, 51
Park, H.-Y., see Kim, H.-K. **59**, 129
Pishdad, G.R., The care of insulin-dependent diabetic patients in Iran **59**, 163

Rabasa-Lhoret, R., see Josse, R.G. **59**, 37
Rais, N., see Mattoo, V. **59**, 137
Ren, Y., see Tian, H. **59**, 63
Rewers, M., see Graves, P.M. **59**, 51
Rodger, N.W., see Josse, R.G. **59**, 37
Ross, S.A., see Josse, R.G. **59**, 37

Rotbart, H.A., see Graves, P.M. **59**, 51
Ryan, E.A., see Josse, R.G. **59**, 37

Sanke, T., see Suzuki, S. **59**, 207
Sato, J., see Hu, X. **59**, 103
Sato, Y., see Hu, X. **59**, 103
Sawada, M., see Fukui, M. **59**, 153
Schwarzenhofer, M., see Mattoo, V. **59**, 137
Seino, Y., see Kuroe, A. **59**, 71
Seino, Y., see Suzuki, S. **59**, 207
Seino, Y., see Yasuda, K. **59**, 113
Shaw, J.E., see Simpson, R.W. **59**, 165
Shigeta, M., see Fukui, M. **59**, 153
Shihara, N., see Yasuda, K. **59**, 113
Shimowada, K., see Yasuda, K. **59**, 113
Short, B., see Vazquez, J.R. **59**, 123
Simpson, R.W., J.E. Shaw, P.Z. Zimmet, The prevention of type 2 diabetes — lifestyle change or pharmacotherapy? A challenge for the 21st century **59**, 165
Šitum, M., see Škrabić, V. **59**, 31
Škrabić, V., T. Zemunik, M. Šitum, J. Terzić, Vitamin D receptor polymorphism and susceptibility to type 1 diabetes in the Dalmatian population **59**, 31
Stanley, W.C., see Martinez, D.A. **59**, 1
Suh, C.-J., see Kim, H.-K. **59**, 129
Sung, F.-C., see Wei, J.-N. **59**, 201
Suzuki, H., see Kuroe, A. **59**, 71
Suzuki, N., see Yasuda, K. **59**, 113
Suzuki, S., Y. Oka, T. Kadowaki, A. Kanatsuka, T. Kuzuya, M. Kobayashi, T. Sanke, Y. Seino, K. Nanjo, Clinical features of diabetes mellitus with the mitochondrial DNA 3243 (A–G) mutation in Japanese: Maternal inheritance and mitochondria-related complications **59**, 207
Suzuki, Y., Y. Atsumi, K. Matusoka, Alternative site testing increases compliance of SMBG (preliminary study of 3 years cohort trials) **59**, 233

Tada, H., see Ikehara, K. **59**, 25
Tamon, A., see Yasuda, K. **59**, 113
Taniguchi, A., see Kuroe, A. **59**, 71
Tankova, T., D. Koev, L. Dakovska, G. Kirilov, The effect of repaglinide on insulin secretion and oxidative stress in type 2 diabetic patients **59**, 43
Terzić, J., see Škrabić, V. **59**, 31
Tessier, D., see Josse, R.G. **59**, 37
Tian, H., L. Han, Y. Ren, X. Li, J. Liang, Lipoprotein(a) level and lipids in type 2 diabetic patients and their normoglycemic first-degree relatives in type 2 diabetic pedigrees **59**, 63
Tojo, A., see Onozato, M.L. **59**, 83
Tounsi, H., see Mattoo, V. **59**, 137
Tsai, S.-T., see Li, C.-L. **59**, 225
Tsubakimori, S., see Yamamoto, I. **59**, 219
Tsuda, K., see Yasuda, K. **59**, 113

Uno, M., see Yasuda, K. **59**, 113
Usami, M., see Kuroe, A. **59**, 71
Usui, S., see Kazama, H. **59**, 181

Vailas, A.C., see Martinez, D.A. **59**, 1
Vazquez, J.R., B. Short, A.H. Findlow, B.P. Nixon, A.J.M. Boulton, D.G. Armstrong, Outcomes of hyaluronan therapy in diabetic foot wounds **59**, 123

Wada, K., see Fukui, M. **59**, 153
Wei, J.-N., L.-M. Chuang, C.-C. Lin, C.-C. Chiang, R.-S. Lin, F.-C. Sung, Childhood diabetes identified in mass urine screening program in Taiwan, 1993–1999 **59**, 201
Wolever, T.M.S., see Josse, R.G. **59**, 37

Xu, M., see Hu, X. **59**, 103

Yale, J.-F., see Josse, R.G. **59**, 37
Yamada, Y., see Kuroe, A. **59**, 71
Yamamoto, I., J. Fujitsu, S. Nohnen, T. Igarashi, T. Motomura, M. Inaba, S. Tsubakimori, J. Azuma, Association of plasma PAF acetylhydrolase gene polymorphism with IMT of carotid arteries in Japanese type 2 diabetic patients **59**, 219
Yasuda, K., K. Shimowada, M. Uno, H. Odaka, T. Adachi, N. Shihara, N. Suzuki, A. Tamon, K. Nagashima, M. Hosokawa, K. Tsuda, Y. Seino, Long-term therapeutic effects of voglibose, a potent intestinal alpha-glucosidase inhibitor, in spontaneous diabetic GK rats **59**, 113
Yasuda, K., see Kuroe, A. **59**, 71
Yoon, H.-J., see Kim, H.-K. **59**, 129
Yoshikawa, T., see Fukui, M. **59**, 153

Zemunik, T., see Škrabić, V. **59**, 31
Zimmet, P.Z., see Simpson, R.W. **59**, 165

ELSEVIER

Diabetes Research and Clinical Practice 59 (2003) 239–242

DIABETES RESEARCH AND CLINICAL PRACTICE

www.elsevier.com/locate/diabres

# Subject index of volume 59

**Acarbose**; Elderly; Type 2 diabetes **59**, 37

**ACE inhibitor**; Diabetes; NAD(P)H oxidase; Albuminuria; Dipyridamole **59**, 83

**Albuminuria**; Diabetes; NAD(P)H oxidase; Dipyridamole; ACE inhibitor **59**, 83

**Amputation**; Diabetes; Foot; Ulcer; Wound **59**, 123

**Angiographically documented**; Postchallenge hyperglycemia; Hyperinsulinemia; Coronary atherosclerosis **59**, 129

**Angioplasty**; Diabetes; High glucose; Growth factors; Coronary disease; Vascular smooth muscle **59**, 93

**Angiotensin II**; Protein kinase C; Fibronectin; Type IV collagen; Mesangial cells **59**, 25

**Atherosclerosis**; Type 2 diabetes; Augmentation **59**, 153

**Augmentation**; Type 2 diabetes; Atherosclerosis **59**, 153

**Beta-cell autoimmunity**; Type 1 diabetes; Enterovirus; Prospective study **59**, 51

**Bezafibrate**; Diabetes mellitus; Remnant-like lipoprotein particles; Lipoprotein subclass; Pravastatin; High performance liquid chromatography **59**, 181

**β-Cell dysfunction**; Insulin resistance; Impaired fasting glucose; Impaired glucose tolerance **59**, 225

**Chinese herbal medicine**; Gosha-jinki-gan; Insulin resistance; Euglycemic clamp; Nitric oxide **59**, 103

**Chronic renal failure**; Postprandial blood glucose; Nateglinide; Nateglinide metabolite **59**, 191

**Computerized**; Diabetes mellitus; Epidemiology; Hospitalizations; Medical records systems **59**, 145

**Coronary atherosclerosis**; Postchallenge hyperglycemia; Hyperinsulinemia; Angiographically documented **59**, 129

**Coronary disease**; Diabetes; High glucose; Angioplasty; Growth factors; Vascular smooth muscle **59**, 93

**Cross-links**; Diabetes; Fibrosis; Interstitial space; Remodeling **59**, 1

**Dalmatia**; Vitamin D receptor; Genotype; Type 1 diabetes; Genetic susceptibility **59**, 31

**Deafness**; Mitochondrial DNA; Diabetes mellitus; Insulin; Mitochondrial encephalomyopathy; Wolff–Parkinson–White syndrome; Sick sinus syndrome; Diabetic neuropathy; Diabetic retinopathy; Diabetic nephropathy **59**, 207

**Diabetes**; Fibrosis; Interstitial space; Remodeling; Cross-links **59**, 1

**Diabetes**; Foot; Ulcer; Amputation; Wound **59**, 123

**Diabetes**; High glucose; Angioplasty; Growth factors; Coronary disease; Vascular smooth muscle **59**, 93

**Diabetes mellitus**; Epidemiology; Hospitalizations; Medical records systems; Computerized **59**, 145

**Diabetes mellitus**; Mitochondrial DNA; Insulin; Deafness; Mitochondrial encephalomyopathy; Wolff–Parkinson–White syndrome; Sick sinus syndrome; Diabetic neuropathy; Diabetic retinopathy; Diabetic nephropathy **59**, 207

**Diabetes mellitus**; Ocular surface disorders; Tear function tests **59**, 195

PII: S0168-8227(03)00025-1

**Diabetes mellitus**; Remnant-like lipoprotein particles; Lipoprotein subclass; Bezafibrate; Pravastatin; High performance liquid chromatography **59**, 181

**Diabetes mellitus**; School children; Sex difference; Taiwan **59**, 201

**Diabetes**; NAD(P)H oxidase; Albuminuria; Dipyridamole; ACE inhibitor **59**, 83

**Diabetes prevention**; Type 2 diabetes; Lifestyle factors; Pharmacotherapy; Prevention trials **59**, 165

**Diabetic nephropathy**; Mitochondrial DNA; Diabetes mellitus; Insulin; Deafness; Mitochondrial encephalomyopathy; Wolff–Parkinson–White syndrome; Sick sinus syndrome; Diabetic neuropathy; Diabetic retinopathy **59**, 207

**Diabetic neuropathy**; Mitochondrial DNA; Diabetes mellitus; Insulin; Deafness; Mitochondrial encephalomyopathy; Wolff–Parkinson–White syndrome; Sick sinus syndrome; Diabetic retinopathy; Diabetic nephropathy **59**, 207

**Diabetic retinopathy**; Mitochondrial DNA; Diabetes mellitus; Insulin; Deafness; Mitochondrial encephalomyopathy; Wolff–Parkinson–White syndrome; Sick sinus syndrome; Diabetic neuropathy; Diabetic nephropathy **59**, 207

**Dipyridamole**; Diabetes; NAD(P)H oxidase; Albuminuria; ACE inhibitor **59**, 83

**Disaccharidase**; Sucrase–isomaltase; Small intestine; Oral hypoglycemic agent; Postprandial hyperglycemia **59**, 113

**Dyslipidemia**; Lipoprotein(a); Type 2 diabetes mellitus; First-degree relatives; Genetic correlation **59**, 63

**Elderly**; Acarbose; Type 2 diabetes **59**, 37

**Elderly patient**; Plasma PAF acetylhydrolase; G994T polymorphism; Intima media thickness; Type2 diabetes **59**, 219

**Enterovirus**; Type 1 diabetes; Beta-cell autoimmunity; Prospective study **59**, 51

**Epidemiology**; Diabetes mellitus; Hospitalizations; Medical records systems; Computerized **59**, 145

**Euglycemic clamp**; Chinese herbal medicine; Gosha-jinki-gan; Insulin resistance; Nitric oxide **59**, 103

**Fasting**; Insulin; Lispro; Ramadan; Type 2 diabetes; Postprandial glucose control **59**, 137

**Fibronectin**; Angiotensin II; Protein kinase C; Type IV collagen; Mesangial cells **59**, 25

**Fibrosis**; Diabetes; Interstitial space; Remodeling; Cross-links **59**, 1

**First-degree relatives**; Lipoprotein(a); Type 2 diabetes mellitus; Dyslipidemia; Genetic correlation **59**, 63

**Foot**; Diabetes; Ulcer; Amputation; Wound **59**, 123

**Genetic correlation**; Lipoprotein(a); Type 2 diabetes mellitus; First-degree relatives; Dyslipidemia **59**, 63

**Genetic susceptibility**; Vitamin D receptor; Genotype; Type 1 diabetes; Dalmatia **59**, 31

**Genotype**; Vitamin D receptor; Type 1 diabetes; Genetic susceptibility; Dalmatia **59**, 31

**Gosha-jinki-gan**; Chinese herbal medicine; Insulin resistance; Euglycemic clamp; Nitric oxide **59**, 103

**Growth factors**; Diabetes; High glucose; Angioplasty; Coronary disease; Vascular smooth muscle **59**, 93

**G994T polymorphism**; Plasma PAF acetylhydrolase; Intima media thickness; Type2 diabetes; Elderly patient **59**, 219

**High glucose**; Diabetes; Angioplasty; Growth factors; Coronary disease; Vascular smooth muscle **59**, 93

**High performance liquid chromatography**; Diabetes mellitus; Remnant-like lipoprotein particles; Lipoprotein subclass; Bezafibrate; Pravastatin **59**, 181

**HOMA β-cell**; ISI composite; Insulinogenic index; HOMA-IR **59**, 71

**HOMA-IR**; ISI composite; Insulinogenic index; HOMA β-cell **59**, 71

**Hospitalizations**; Diabetes mellitus; Epidemiology; Medical records systems; Computerized **59**, 145

**Hyperinsulinemia**; Postchallenge hyperglycemia; Coronary atherosclerosis; Angiographically documented **59**, 129

**Impaired fasting glucose**; Insulin resistance; β-Cell dysfunction; Impaired glucose tolerance **59**, 225

**Impaired glucose tolerance**; Insulin resistance; β-Cell dysfunction; Impaired fasting glucose **59**, 225

**Insulin**; Fasting; Lispro; Ramadan; Type 2 diabetes; Postprandial glucose control **59**, 137

**Insulin**; Mitochondrial DNA; Diabetes mellitus; Deafness; Mitochondrial encephalomyopathy; Wolff–Parkinson–White syndrome; Sick sinus syndrome; Diabetic neuropathy; Diabetic retinopathy; Diabetic nephropathy **59**, 207

**Insulinogenic index**; ISI composite; HOMA-IR; HOMA β-cell **59**, 71

**Insulin resistance**; β-Cell dysfunction; Impaired fasting glucose; Impaired glucose tolerance **59**, 225

**Insulin resistance**; Chinese herbal medicine; Gosha-jinki-gan; Euglycemic clamp; Nitric oxide **59**, 103

**Insulin secretion**; Repaglinide; Oxidative stress; Type 2 diabetes **59**, 43

**Interstitial space**; Diabetes; Fibrosis; Remodeling; Cross-links **59**, 1

**Intima media thickness**; Plasma PAF acetylhydrolase; G994T polymorphism; Type2 diabetes; Elderly patient **59**, 219

**ISI composite**; Insulinogenic index; HOMA-IR; HOMA β-cell **59**, 71

**Lifestyle factors**; Type 2 diabetes; Diabetes prevention; Pharmacotherapy; Prevention trials **59**, 165

**Lipoprotein(a)**; Type 2 diabetes mellitus; First-degree relatives; Dyslipidemia; Genetic correlation **59**, 63

**Lipoprotein subclass**; Diabetes mellitus; Remnant-like lipoprotein particles; Bezafibrate; Pravastatin; High performance liquid chromatography **59**, 181

**Lispro**; Fasting; Insulin; Ramadan; Type 2 diabetes; Postprandial glucose control **59**, 137

**Medical records systems**; Diabetes mellitus; Epidemiology; Hospitalizations; Computerized **59**, 145

**Mesangial cells**; Angiotensin II; Protein kinase C; Fibronectin; Type IV collagen **59**, 25

**Mitochondrial DNA**; Diabetes mellitus; Insulin; Deafness; Mitochondrial encephalomyopathy; Wolff–Parkinson–White syndrome; Sick sinus syndrome; Diabetic neuropathy; Diabetic retinopathy; Diabetic nephropathy **59**, 207

**Mitochondrial encephalomyopathy**; Mitochondrial DNA; Diabetes mellitus; Insulin; Deafness; Wolff–Parkinson–White syndrome; Sick sinus syndrome; Diabetic neuropathy; Diabetic retinopathy; Diabetic nephropathy **59**, 207

**NAD(P)H oxidase**; Diabetes; Albuminuria; Dipyridamole; ACE inhibitor **59**, 83

**Nateglinide**; Chronic renal failure; Postprandial blood glucose; Nateglinide metabolite **59**, 191

**Nateglinide metabolite**; Chronic renal failure; Postprandial blood glucose; Nateglinide **59**, 191

**Nitric oxide**; Chinese herbal medicine; Gosha-jinki-gan; Insulin resistance; Euglycemic clamp **59**, 103

**Non-insulin-dependent diabetes mellitus**; Zucker rats; Thromboxane $A_2$ vascular reactivity; Platelet aggregation **59**, 11

**Ocular surface disorders**; Diabetes mellitus; Tear function tests **59**, 195

**Oral hypoglycemic agent**; Sucrase–isomaltase; Small intestine; Disaccharidase; Postprandial hyperglycemia **59**, 113

**Oxidative stress**; Repaglinide; Insulin secretion; Type 2 diabetes **59**, 43

**Pharmacotherapy**; Type 2 diabetes; Diabetes prevention; Lifestyle factors; Prevention trials **59**, 165

**Plasma PAF acetylhydrolase**; G994T polymorphism; Intima media thickness; Type2 diabetes; Elderly patient **59**, 219

**Platelet aggregation**; Non-insulin-dependent diabetes mellitus; Zucker rats; Thromboxane $A_2$ vascular reactivity **59**, 11

**Postchallenge hyperglycemia**; Hyperinsulinemia; Coronary atherosclerosis; Angiographically documented **59**, 129

**Postprandial blood glucose**; Chronic renal failure; Nateglinide; Nateglinide metabolite **59**, 191

**Postprandial glucose control**; Fasting; Insulin; Lispro; Ramadan; Type 2 diabetes **59**, 137

**Postprandial hyperglycemia**; Sucrase–isomaltase; Small intestine; Disaccharidase; Oral hypoglycemic agent **59**, 113

**Pravastatin**; Diabetes mellitus; Remnant-like lipoprotein particles; Lipoprotein subclass; Bezafibrate; High performance liquid chromatography **59**, 181

**Prevention trials**; Type 2 diabetes; Diabetes prevention; Lifestyle factors; Pharmacotherapy **59**, 165

**Prospective study**; Type 1 diabetes; Enterovirus; Beta-cell autoimmunity **59**, 51

**Protein kinase C**; Angiotensin II; Fibronectin; Type IV collagen; Mesangial cells **59**, 25

**Ramadan**; Fasting; Insulin; Lispro; Type 2 diabetes; Postprandial glucose control **59**, 137

**Remnant-like lipoprotein particles**; Diabetes mellitus; Lipoprotein subclass; Bezafibrate; Pravastatin; High performance liquid chromatography **59**, 181

**Remodeling**; Diabetes; Fibrosis; Interstitial space; Cross-links **59**, 1

**Repaglinide**; Insulin secretion; Oxidative stress; Type 2 diabetes **59**, 43

**School children**; Diabetes mellitus; Sex difference; Taiwan **59**, 201

**Sex difference**; Diabetes mellitus; School children; Taiwan **59**, 201

**Sick sinus syndrome**; Mitochondrial DNA; Diabetes mellitus; Insulin; Deafness; Mitochondrial encephalomyopathy; Wolff–Parkinson–White syndrome; Diabetic neuropathy; Diabetic retinopathy; Diabetic nephropathy **59**, 207

**Small intestine**; Sucrase–isomaltase; Disaccharidase; Oral hypoglycemic agent; Postprandial hyperglycemia **59**, 113

**Sucrase–isomaltase**; Small intestine; Disaccharidase; Oral hypoglycemic agent; Postprandial hyperglycemia **59**, 113

**Taiwan**; Diabetes mellitus; School children; Sex difference **59**, 201

**Tear function tests**; Diabetes mellitus; Ocular surface disorders **59**, 195

**Thromboxane $A_2$ vascular reactivity**; Non-insulin-dependent diabetes mellitus; Zucker rats; Platelet aggregation **59**, 11

**Type 2 diabetes**; Acarbose; Elderly **59**, 37

**Type 2 diabetes**; Atherosclerosis; Augmentation **59**, 153

**Type 2 diabetes**; Diabetes prevention; Lifestyle factors; Pharmacotherapy; Prevention trials **59**, 165

**Type 1 diabetes**; Enterovirus; Beta-cell autoimmunity; Prospective study **59**, 51

**Type 2 diabetes**; Fasting; Insulin; Lispro; Ramadan; Postprandial glucose control **59**, 137

**Type 2 diabetes mellitus**; Lipoprotein(a); First-degree relatives; Dyslipidemia; Genetic correlation **59**, 63

**Type2 diabetes**; Plasma PAF acetylhydrolase; G994T polymorphism; Intima media thickness; Elderly patient **59**, 219

**Type 2 diabetes**; Repaglinide; Insulin secretion; Oxidative stress **59**, 43

**Type 1 diabetes**; Vitamin D receptor; Genotype; Genetic susceptibility; Dalmatia **59**, 31

**Type IV collagen**; Angiotensin II; Protein kinase C; Fibronectin; Mesangial cells **59**, 25

**Ulcer**; Diabetes; Foot; Amputation; Wound **59**, 123

**Vascular smooth muscle**; Diabetes; High glucose; Angioplasty; Growth factors; Coronary disease **59**, 93

**Vitamin D receptor**; Genotype; Type 1 diabetes; Genetic susceptibility; Dalmatia **59**, 31

**Wolff–Parkinson–White syndrome**; Mitochondrial DNA; Diabetes mellitus; Insulin; Deafness; Mitochondrial encephalomyopathy; Sick sinus syndrome; Diabetic neuropathy; Diabetic retinopathy; Diabetic nephropathy **59**, 207

**Wound**; Diabetes; Foot; Ulcer; Amputation **59**, 123

**Zucker rats**; Non-insulin-dependent diabetes mellitus; Thromboxane $A_2$ vascular reactivity; Platelet aggregation **59**, 11